Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease.

Peripheral T-cell lymphoma in a patient with Crohn's disease. BMJ Case Rep (2013) 0.75

Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med (2005) 14.50

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet (2002) 14.14

Primary central nervous system lymphoma in a patient treated with natalizumab. Ann Neurol (2009) 6.96

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology (2006) 6.88

Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med (2004) 6.77

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology (2006) 6.36

Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer (2008) 6.13

Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet (1984) 5.74

Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet (2009) 5.03

Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst (1993) 4.59

Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum (2004) 4.57

Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med (2007) 4.56

Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology (2001) 4.28

Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med (2007) 4.07

A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology (2005) 4.06

Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology (2008) 3.98

Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut (2005) 3.86

Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet (1998) 3.77

Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum (2002) 3.63

Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology (2008) 3.52

The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology (2004) 3.50

Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology (2007) 3.32

AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst (2007) 3.28

Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant (2004) 3.25

The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol (1988) 3.24

Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr (2007) 3.20

Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet (1996) 3.15

Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chronic Dis (1978) 3.08

CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest (2003) 2.97

Risks and benefits of infliximab for the treatment of Crohn's disease. Clin Gastroenterol Hepatol (2006) 2.88

Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol (2009) 2.72

6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med (1989) 2.70

Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis (2008) 2.61

Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis (2006) 2.51

A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J Dermatolog Treat (2004) 2.45

Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol (2006) 2.44

Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J Clin Oncol (1996) 2.44

Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med (1993) 2.27

Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol (2008) 2.25

Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut (2000) 2.17

Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol (2008) 2.15

Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study. Ann Rheum Dis (1988) 2.09

Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet (1994) 2.04

Lymphoma developing in a patient with rheumatoid arthritis taking low dose weekly methotrexate. J Rheumatol (1991) 2.00

Immune deficiency and risk for malignancy among persons with AIDS. J Acquir Immune Defic Syndr (2003) 1.96

Malignancy after transplantation. Transplantation (2005) 1.92

Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol (2003) 1.91

Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut (2004) 1.87

The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. Am J Gastroenterol (1996) 1.83

Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology (2002) 1.80

Immunosuppressant medications and mortality in inflammatory bowel disease. Am J Gastroenterol (2008) 1.80

Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review. Drugs (2007) 1.76

Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. Gastroenterology (2000) 1.74

Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy. Gastroenterology (2007) 1.71

Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation (2004) 1.68

Lymphoma risk in psoriasis: results of the PUVA follow-up study. Arch Dermatol (2006) 1.57

Safety aspects of infliximab in inflammatory bowel disease patients. A retrospective cohort study in 100 patients of a German University Hospital. Digestion (2004) 1.57

Neoplasms of the immune system in rheumatoid arthritis. Am J Med (1985) 1.52

Safety of tumour necrosis factor-alpha antagonists. Drug Saf (2004) 1.52

Case report: lymphoma arising in an ileal pouch anal anastomosis after immunomodulatory therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol (2006) 1.50

Epstein-Barr virus-associated lymphoproliferative disease during methotrexate therapy for psoriasis. Arch Dermatol (1997) 1.43

Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Aliment Pharmacol Ther (2002) 1.41

Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum (2008) 1.39

Rheumatoid arthritis and cancer studies based on linking nationwide registries in Finland. Am J Med (1985) 1.29

Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol (2001) 1.24

Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine. Am J Gastroenterol (1999) 1.21

Psoriasis, its treatment, and cancer in a cohort of Finnish patients. J Invest Dermatol (2000) 1.15

Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update. J Pediatr Gastroenterol Nutr (2009) 1.14

Infliximab in Crohn's disease: first anniversary clinical experience. Am J Gastroenterol (2000) 1.14

Cancer and rheumatoid arthritis: epidemiologic considerations. Am J Med (1985) 1.14

The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up. Aliment Pharmacol Ther (2009) 1.13

Hepatosplenic T-cell lymphoma in a young man with Crohn's disease: case report and literature review. Clin Lymphoma Myeloma Leuk (2010) 1.13

Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease. Ann Pharmacother (2007) 1.10

Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis. Arch Intern Med (2008) 1.09

Malignancies in renal transplantation: an unmet medical need. Nephrol Dial Transplant (2007) 1.08

Risk of cancer in inflammatory bowel disease treated with azathioprine: a UK population-based case-control study. Am J Gastroenterol (2010) 1.07

Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease. Am J Gastroenterol (2009) 1.07

Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease. J Pediatr Gastroenterol Nutr (2005) 1.03

Hepatosplenic gamma/delta T-cell lymphoma in immunocompromised patients. Report of two cases and review of literature. Am J Clin Pathol (2001) 1.03

The risk of neoplasms in patients treated with cyclosporine A. J Autoimmun (1989) 1.02

Methotrexate-associated lymphoma in patients with rheumatoid arthritis: report of two cases. Arthritis Rheum (1996) 1.00

Effect of cyclosporin A on DNA repair and cancer incidence in kidney transplant recipients. J Lab Clin Med (2001) 0.97

Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se? Transplantation (2003) 0.96

Immune surveillance of EBV-infected B cells and the development of non-Hodgkin lymphomas in immunocompromised patients. Leuk Lymphoma (2008) 0.95

Association of methotrexate, rheumatoid arthritis and lymphoma: report of 2 cases and literature review. J Rheumatol (1992) 0.93

The ten-year single-center experience with 6-mercaptopurine in the treatment of inflammatory bowel disease. J Clin Gastroenterol (2005) 0.93

Hepatosplenic T-cell lymphoma in a patient with Crohn's disease who received infliximab therapy. Leuk Lymphoma (2007) 0.91

CD30+ T-cell lymphoma in a patient with psoriasis treated with ciclosporin and infliximab. Br J Dermatol (2003) 0.90

Long-term survival in two patients with hepatosplenic T cell lymphoma treated with interferon-alpha. Leuk Lymphoma (2008) 0.87

Neoplastic lymphoproliferation in autoimmune disease: an updated review. Clin Immunol Immunopathol (1992) 0.87

Austrian infliximab experience in Crohn's disease: a nationwide cooperative study with long-term follow-up. Eur J Gastroenterol Hepatol (2004) 0.83

Rectal malignant lymphoma complicating ulcerative colitis treated with long-term cyclosporine A. J Gastroenterol Hepatol (2006) 0.81

Methotrexate related B lymphoproliferative disease in a patient with rheumatoid arthritis. Role of Epstein-Barr virus infection. J Rheumatol (1995) 0.81

Pulmonary lymphoma developed during long-term methotrexate therapy for psoriasis. Respirology (2007) 0.79

Methotrexate-induced pulmonary lymphoma. Chest (2003) 0.79

Infliximab use in Crohn's disease. Expert Opin Biol Ther (2005) 0.78

Epstein-Barr virus-associated lymphoproliferative disease after long-standing cyclosporine therapy for psoriasis: a case of spontaneous regression. J Am Acad Dermatol (2005) 0.78

Lessons learned in the use of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis. Curr Rheumatol Rep (2003) 0.77

Adult T-cell lymphoma/leukaemia developing in a patient with psoriasis treated with long-term cyclosporine. Acta Derm Venereol (2006) 0.76

Epstein-Barr virus-associated lymphoma in a patient with rheumatoid arthritis treated with cyclosporine. N Engl J Med (1992) 0.76

Linking long-term dietary patterns with gut microbial enterotypes. Science (2011) 17.30

Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA (2006) 9.53

Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med (2013) 9.44

The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology (2002) 4.98

Sampling and pyrosequencing methods for characterizing bacterial communities in the human gut using 16S sequence tags. BMC Microbiol (2010) 4.97

Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA (2011) 3.58

Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology (2004) 3.57

The human gut virome: inter-individual variation and dynamic response to diet. Genome Res (2011) 3.32

Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol (2002) 3.01

Mortality associated with medical therapy versus elective colectomy in ulcerative colitis: a cohort study. Ann Intern Med (2014) 2.73

Rapid evolution of the human gut virome. Proc Natl Acad Sci U S A (2013) 2.53

Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA (2012) 2.51

Use of abdominopelvic computed tomography in emergency departments and rates of urgent diagnoses in Crohn's disease. Clin Gastroenterol Hepatol (2011) 2.40

The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol (2007) 2.32

Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998 to 2010. Gastroenterology (2012) 2.26

Development of an internet-based cohort of patients with inflammatory bowel diseases (CCFA Partners): methodology and initial results. Inflamm Bowel Dis (2012) 2.23

Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol (2006) 2.16

Increased risk for demyelinating diseases in patients with inflammatory bowel disease. Gastroenterology (2005) 2.15

Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum (2012) 2.15

Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology (2006) 2.14

Initiation of anti-TNF therapy and the risk of optic neuritis: from the safety assessment of biologic ThERapy (SABER) Study. Am J Ophthalmol (2012) 2.14

AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology (2010) 2.09

An optimized patient-reported ulcerative colitis disease activity measure derived from the Mayo score and the simple clinical colitis activity index. Inflamm Bowel Dis (2014) 2.05

Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy. Arthritis Care Res (Hoboken) (2015) 2.03

Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology (2003) 1.94

Trends in the use of biologic agents among rheumatoid arthritis patients enrolled in the US medicare program. Arthritis Care Res (Hoboken) (2013) 1.92

Risk of kidney injury following oral phosphosoda bowel preparations. J Am Soc Nephrol (2007) 1.89

Renal function after orthotopic liver transplantation is predicted by duration of pretransplantation creatinine elevation. Liver Transpl (2005) 1.87

Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care (2011) 1.83

Time trends in therapies and outcomes for adult inflammatory bowel disease, Northern California, 1998-2005. Gastroenterology (2009) 1.74

Incidence and prevalence of inflammatory bowel disease in a Northern California managed care organization, 1996-2002. Am J Gastroenterol (2008) 1.72

Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study. J Natl Cancer Inst (2012) 1.69

Cancer incidence in The Health Improvement Network. Pharmacoepidemiol Drug Saf (2009) 1.65

Archaea and fungi of the human gut microbiome: correlations with diet and bacterial residents. PLoS One (2013) 1.64

Validity of The Health Improvement Network (THIN) for epidemiologic studies of hepatitis C virus infection. Pharmacoepidemiol Drug Saf (2009) 1.61

Hypervariable loci in the human gut virome. Proc Natl Acad Sci U S A (2012) 1.58

A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease. Gastroenterology (2004) 1.51

Anti-TNF antibodies for Crohn's disease--in pursuit of the perfect clinical trial. N Engl J Med (2007) 1.50

Structure-constrained sparse canonical correlation analysis with an application to microbiome data analysis. Biostatistics (2012) 1.49

Influence of alcohol use, race, and viral coinfections on spontaneous HCV clearance in a US veteran population. Hepatology (2004) 1.49

Communication outcomes in audiologic reporting. J Am Acad Audiol (2011) 1.48

Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA (2013) 1.45

Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum (2012) 1.43

Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Am J Gastroenterol (2011) 1.39

A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis. Gastroenterology (2006) 1.39

Quality indicators for inflammatory bowel disease: development of process and outcome measures. Inflamm Bowel Dis (2013) 1.33

The impact of increased body mass index on the clinical course of Crohn's disease. Clin Gastroenterol Hepatol (2006) 1.32

Study design for a comprehensive assessment of biologic safety using multiple healthcare data systems. Pharmacoepidemiol Drug Saf (2011) 1.30

Incidence, prevalence, and time trends of pediatric inflammatory bowel disease in Northern California, 1996 to 2006. J Pediatr (2010) 1.30

Trends in hospitalization rates for inflammatory bowel disease in the United States. Clin Gastroenterol Hepatol (2007) 1.30

Potential association between the oral tetracycline class of antimicrobials used to treat acne and inflammatory bowel disease. Am J Gastroenterol (2010) 1.28

Dietary patterns and self-reported associations of diet with symptoms of inflammatory bowel disease. Dig Dis Sci (2012) 1.27

A tool kit for quantifying eukaryotic rRNA gene sequences from human microbiome samples. Genome Biol (2012) 1.17

The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety. Am J Gastroenterol (2011) 1.15

Chronic proton pump inhibitor therapy and the risk of colorectal cancer. Gastroenterology (2007) 1.13

Type 2 diabetes mellitus and the risk of colorectal cancer. Clin Gastroenterol Hepatol (2005) 1.12

Fungi of the murine gut: episodic variation and proliferation during antibiotic treatment. PLoS One (2013) 1.11

Validation of The Health Improvement Network (THIN) database for epidemiologic studies of chronic kidney disease. Pharmacoepidemiol Drug Saf (2011) 1.11

The impact of bariatric surgery on menstrual patterns. Obes Surg (2006) 1.08

Prevalence of colorectal cancer surveillance for ulcerative colitis in an integrated health care delivery system. Gastroenterology (2010) 1.07

No increased risk of myocardial infarction among patients with ulcerative colitis or Crohn's disease. Clin Gastroenterol Hepatol (2011) 1.05

Patient preferences for surgical versus medical therapy for ulcerative colitis. Inflamm Bowel Dis (2014) 1.05

Leaf respiration at different canopy positions in sweetgum (Liquidambar styraciflua) grown in ambient and elevated concentrations of carbon dioxide in the field. Tree Physiol (2002) 1.04

Safety profile of IBD: lymphoma risks. Gastroenterol Clin North Am (2009) 1.02

Gastroenterologists' attitudes and self-reported practices regarding inflammatory bowel disease. Inflamm Bowel Dis (2008) 1.02

Cardiovascular risk in rheumatoid arthritis: comparing TNF-α blockade with nonbiologic DMARDs. Am J Med (2013) 1.01

Temporal and within practice variability in the health improvement network. Pharmacoepidemiol Drug Saf (2011) 1.01

Patterns of complementary and alternative medicine use in a population of pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis (2004) 1.00

Validation of a coding algorithm to identify patients with hepatocellular carcinoma in an administrative database. Pharmacoepidemiol Drug Saf (2012) 1.00

Chronic statin therapy and the risk of colorectal cancer. Pharmacoepidemiol Drug Saf (2008) 1.00

Comparative Effectiveness of Nutritional and Biological Therapy in North American Children with Active Crohn's Disease. Inflamm Bowel Dis (2015) 0.99

Diet, the human gut microbiota, and IBD. Anaerobe (2013) 0.98

State of the art: IBD therapy and clinical trials in IBD. Inflamm Bowel Dis (2005) 0.98

Food and the gut microbiota in inflammatory bowel diseases: a critical connection. Curr Opin Gastroenterol (2012) 0.98

Challenges in IBD research: update on progress and prioritization of the CCFA's research agenda. Inflamm Bowel Dis (2013) 0.97

Secular trends in small-bowel obstruction and adhesiolysis in the United States: 1988-2007. Am J Surg (2012) 0.97

Analysis of the human gut microbiome and association with disease. Clin Gastroenterol Hepatol (2013) 0.96

Improved characterization of medically relevant fungi in the human respiratory tract using next-generation sequencing. Genome Biol (2014) 0.96

Conservation of gene cassettes among diverse viruses of the human gut. PLoS One (2012) 0.96

Crohn's disease and ulcerative colitis are associated with elevated standardized mortality ratios: a meta-analysis. Inflamm Bowel Dis (2013) 0.96

Balancing safety of dietary supplements with the free market. Ann Intern Med (2002) 0.95

Colonic dysplasia and cancer in inflammatory bowel disease. Gastrointest Endosc Clin N Am (2002) 0.94

Passive smoking and inflammatory bowel disease: a meta-analysis. Am J Gastroenterol (2008) 0.93

Distinguishing incident and prevalent diabetes in an electronic medical records database. Pharmacoepidemiol Drug Saf (2013) 0.93

Tumor necrosis factor α inhibitor therapy and cancer risk in chronic immune-mediated diseases. Arthritis Rheum (2013) 0.92

Increasing complexity of clinical research in gastroenterology: implications for the training of clinician-scientists. Am J Gastroenterol (2012) 0.92

Fungal Signature in the Gut Microbiota of Pediatric Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis (2015) 0.91

Inter- and intra-specific variation in nocturnal water transport in Eucalyptus. Tree Physiol (2010) 0.90

Nocturnal stomatal conductance responses to rising [CO2], temperature and drought. New Phytol (2011) 0.90

Engineering the gut microbiota to treat hyperammonemia. J Clin Invest (2015) 0.89

Contribution of higher risk genes and European admixture to Crohn's disease in African Americans. Inflamm Bowel Dis (2012) 0.88

Antibiotic use and the risk of flare of inflammatory bowel disease. Clin Gastroenterol Hepatol (2005) 0.88

Incidence and prevalence of abnormal liver associated enzymes in patients with atrial fibrillation in a routine clinical care population. Pharmacoepidemiol Drug Saf (2008) 0.88

Photosynthetic responses of two eucalypts to industrial-age changes in atmospheric [CO2] and temperature. Plant Cell Environ (2010) 0.88

Medial olivocochlear-induced transient-evoked otoacoustic emission amplitude shifts in individual subjects. J Assoc Res Otolaryngol (2013) 0.87

Site organization and management. Inflamm Bowel Dis (2005) 0.87

Risk of proximal and distal colorectal cancer following flexible sigmoidoscopy: a population-based cohort study. Am J Gastroenterol (2008) 0.87

Risk for active tuberculosis in inflammatory bowel disease patients. Clin Gastroenterol Hepatol (2007) 0.86

Immortal time bias in estimates of mortality among infliximab-treated patients with Crohn's disease. Gut (2010) 0.86

Genes associated with intestinal permeability in ulcerative colitis: changes in expression following infliximab therapy. Inflamm Bowel Dis (2012) 0.86